Skip to main content
Guhan Pharmaceutical Group Co., Ltd. logo

Guhan Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 000590 ISIN · CNE000000701 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,714 across all filing types
Latest filing 2023-05-18 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000590

About Guhan Pharmaceutical Group Co., Ltd.

https://www.tuspharma.cn

Guhan Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and sale of traditional Chinese medicine (TCM) and health-related products. The company is widely recognized for its flagship product, Guhan Yangsheng Jing, which is formulated based on ancient health preservation prescriptions discovered in the Mawangdui Han Dynasty Tombs. Its product portfolio includes oral liquids, tablets, and capsules designed to enhance vitality, support kidney function, and promote overall longevity. The organization integrates classical medical theories with modern pharmaceutical manufacturing processes to ensure product efficacy and safety. Beyond its core TCM offerings, the group engages in the production of chemical drugs and health supplements, targeting markets seeking natural wellness solutions. The company emphasizes the preservation of cultural heritage through the modernization of ancient medical wisdom.

Recent filings

Filing Released Lang Actions
启迪药业-2022年度股东大会法律意见书
Regulatory Filings
2023-05-18 Chinese
关于对外投资设立全资子公司的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's external investment to establish a wholly-owned subsidiary. It details the investment purpose, approval process, and impact on the company. There are no financial statements or detailed financial performance data included. The document is a formal announcement of a corporate action related to capital investment but does not report on financing activities like fundraising or capital structure changes. It is not a full financial report, earnings release, or management report. The content fits best under Capital/Financing Update (CAP) as it informs about a capital investment decision and subsidiary establishment.
2023-05-18 Chinese
第十届监事会第一次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolution from the first meeting of the 10th Supervisory Board of the company, including election of the Supervisory Board Chairman and related details. It contains no financial statements or detailed financial data, but rather governance-related information about board members and meeting outcomes. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management.
2023-05-18 Chinese
2022年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2022 Annual General Meeting (AGM) of 启迪药业集团股份公司. It includes information about the meeting date, attendance, voting results on various proposals including the 2022 annual report, board and supervisory reports, financial statements, profit distribution, appointment of auditors, amendments to the articles of association, and election of board and supervisory members. The document is not the report itself but the official announcement of the voting results and resolutions from the AGM. It does not contain the full annual report or financial statements but summarizes the outcomes of the shareholder votes. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length (5778 characters) and content confirm it is a full announcement rather than a brief notice or a report publication announcement.
2023-05-18 Chinese
第十届董事会第一次会议决议公告
Board/Management Information Classification · 100% confidence The document is a detailed announcement of the resolutions passed at the first meeting of the 10th Board of Directors of the company, including election of chairman, vice chairman, appointment of board secretary, senior management appointments, and internal organizational adjustments. It includes biographies of the newly appointed directors and senior management. The content focuses on board and management changes rather than financial results, audit opinions, or shareholder voting results. There is no indication of financial data or earnings information. The document is not a report publication announcement or a certification. Therefore, it fits the category of Board/Management Information (MANG).
2023-05-18 Chinese
公司章程（2023年5月）
Governance Information Classification · 100% confidence The document is a detailed company charter (公司章程) for 启迪药业集团股份公司, including comprehensive sections on company governance, shareholder rights, board structure, and meeting procedures. It references approvals by various shareholder meetings over multiple years and includes detailed governance rules and procedures. There is no indication that this is an announcement or summary; rather, it is the full text of the company's articles of association, which is a governance document. Therefore, the document fits the category of Governance Information (CGR). The document length (15,000 characters) and content confirm it is not a brief announcement or a report publication notice but a substantive governance report.
2023-05-18 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.